Accelerating introduction of new vaccines: Barriers to introduction and lessons learned from the recent Haemophilus influenzae type b vaccine experience

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 366, Issue 1579, 2011, Pages 2827-2832

  Hajjeh, Rana ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Global alliance for vaccines and immunization; Haemophilus influenza type b; Hib initiative; Vaccination

Indexed keywords

CHILD MORTALITY; DECISION MAKING; DEVELOPING WORLD; GLOBAL PERSPECTIVE; HEALTH POLICY; IMMUNIZATION; IMPLEMENTATION PROCESS; INFLUENZA; MILLENIUM DEVELOPMENT GOAL; POLICY ANALYSIS; POLICY IMPLEMENTATION; STAKEHOLDER; STRATEGIC APPROACH; SUSTAINABILITY; VACCINATION; VACCINE;

HAEMOPHILUS INFLUENZAE; HAEMOPHILUS INFLUENZAE SEROTYPE B; ROTAVIRUS;

EID: 80052470870     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2011.0046     Document Type: Review

References (22)

1. Black, R. E. et al. 2010 Global, regional and national causes of child mortality in 2008: a systematic analysis. Lancet 375, 1969-1987. (doi:10.1016/S0140-6736(10) 60549-1)
2. Watt, J. P. W. L. et al. 2009 Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 374, 903-911. (doi:10. 1016/S0140-6736(09)61203-4)
3. Levine, O. S., Cherian, T., Shah, R. & Batson, A. 2004 PneumoADIP: an example of translational research to accelerate pneumococcal vaccination in developing countries. J. Health Popul. Nutr. 22, 268-274.
4. Bloom, D. E., Canning, D. & Weston, M. 2005 The value of vaccination. World Econ. 6, 15.
5. Ojo, L. et al. 2010 Global use of Haemophilus influenzae type b conjugate vaccine: an update of accelerated adoption in the developing world. Vaccine 28, 7117-7122. (doi:10.1016/j.vaccine.2010.07.074)
6. Shearer, J., Stack, M. & Richmond, M. 2010 Accelerating national decisions to adopt Haemophilus influenzae type b vaccine: a global multivariate analysis. PLoS Med. 16, e1000249. (doi:10.1371/journal.pmed.1000249)
7. Munira, S. & Fritzen, S. 2007 What influences government adoption of vaccines in developing countries? A policy process analysis. Soc. Sci. Med. 65, 1751-1764. (doi:10.1016/j.socscimed.2007.05.054)
8. Wenger, J. D., DiFabio, J., Landaverde, J. M., Levine, O. S. & Gaafar, T. 1999 Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four 'newly adopting' countries. Vaccine 18, 736-742. (doi:10.1016/S0264-410X(99)00269-8)
9. Widdus, R. 1999 Introduction of vaccines into the Third World. C. R. Acad. Sci. III 322, 999-1010.
10. Lydon, P., Levine, R., Makinen, M., Brenzel, L., Mitchell, V., Milstien, J. B., Kamara, L. & Landry, S. 2008 Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability? Vaccine 26, 6706-6716. (doi:10. 1016/j.vaccine.2008.10.015)
11. Rossi, I. A., Zuber, P. L., Dumolard, L., Walker, D. G. & Watt, J. 2007 Introduction of Hib vaccine into national immunization programmes: a descriptive analysis of global trends. Vaccine 25, 7075-7080. (doi:10.1016/j. vaccine.2007.07.058)
12. World Health Organization 2004 WHO position statement on Hib conjugate vaccines. Wkly Epidemiol. Rec. 79, 173.
13. World Health Organization 2006 WHO position paper on Hib conjugate vaccines.Wkly Epidemiol. Rec. 81, 445-452.
14. Danovaro-Holliday, M. C., Garcia, S., de Quadros, C., Tambini, G. & Andrus, J. K. 2008 Progress in vaccination against Haemophilus influenzae type b in the Americas. PLoS Med. 5, e87. (doi:10.1371/journal. pmed.0050087)
15. Hajjeh, R. A. et al. 2010 Supporting new vaccine introduction decisions: lessons learned from the Hib Initiative experience. Vaccine 28, 7123-7129. (doi:10. 1016/j.vaccine.2010.07.028)
16. Levine, O. S. et al. 2010 A policy framework for accelerating adoption of new vaccines. Hum. Vaccines 6, 1-4. (doi:10.4161/hv.6.12.13076)
17. Griffiths, U.K.&Miners, A. 2009 Economic evaluations of Haemophilus influenzae type b vaccine: systematic review of the literature. Exp. Rev. Pharmacoecon. Outcomes Res. 9, 333-946. (doi:10.1586/erp.09.38)
18. Mendsaikhan, J. et al. 2009 Childhood bacterialmeningitis in Ulaanbaatar, Mongolia, 2002-2004. Clin. Infect. Dis. 48(Suppl. 2), S141-S146. (doi:10.1086/596493)
19. Cowgill, K. D. et al. 2006 Effectiveness of Haemophilus influenzae type b conjugate vaccine introduction into routine childhood immunization in Kenya. JAMA 296, 671-678. (doi:10.1001/jama.296.6.671)
20. Daza, P. et al. The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence. Vaccine 24, 6232-6239. (doi:10.1016/ j.vaccine.2006.05.076)
21. Lewis, R. F. et al. 2008 Action for child survival: elimination of Haemophilus influenzae type b meningitis in Uganda. Bull. World Health Organ. 86, 292-301. (doi:10.2471/BLT.07.045336)
22. World Health Organization 2005 Vaccine introduction guidelines. See http://whqlibdoc.who.int/hq/2005/WHO_ IVB_05.18.pdf.